-
Pralsetinib, sold
under the
brand name Gavreto, is a
medication approved for RET mutation-positive
medullary thyroid cancer (MTC) and RET fusion-positive...
-
include Pembrolizumab, Larotrectinib, Selpercatinib, Entrectinib, and
Pralsetinib.
Pembrolizumab was
approved by the US Food and Drug
Administration in...
- 2017, the
first selective RET
inhibitors selpercatinib (LOXO-292) and
pralsetinib (BLU-667)
started their first phase I/II
clinical trials in
solid tumors...
-
Avapritinib L01EX19
Ripretinib L01EX21
Tepotinib L01EX22
Selpercatinib L01EX23
Pralsetinib L01EX24
Surufatinib L01EX25
Umbralisib L01EX26
Sitravatinib L01EX27 Capivasertib...
-
Masitinib Midostaurin Nintedanib Odronextamab Pazopanib Pexidartinib Pralsetinib Quizartinib Regorafenib Repotrectinib Ripretinib Selpercatinib Sitravatinib...
-
experimental anticancer medication which acts as a RET inhibitor.
Enbezotinib Pralsetinib Rebecsinib Resigratinib Selpercatinib Vodopivec DM, Hu MI (2022). "RET...
-
myeloma Satralizumab Genentech neuromyelitis optica spectrum disorder Pralsetinib Blueprint Medicines Corp RET fusion-positive non-small cell lung cancer...
- malignancies,
newer selective inhibitors (such as
selpercatinib and
pralsetinib) have
shown significant activity in both
mutations and fusions. The results...
-
Masitinib Midostaurin Nintedanib Odronextamab Pazopanib Pexidartinib Pralsetinib Quizartinib Regorafenib Repotrectinib Ripretinib Selpercatinib Sitravatinib...
-
which acts as a RET inhibitor, as well as an
inhibitor of SRC kinase.
Pralsetinib Rebecsinib Resigratinib Selpercatinib Zeteletinib Repetto M, Crimini...
